Consensus Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-14 EDT			5-day change	1st Jan Change
2.210 ^USD	+3.27%		-10.16%	+41.67%

08-06	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-09	Wall Street Ignores the Sirens

Evolution of the Average Target: Alector, Inc.

Evolution of the Target Price: Alector, Inc.

Changes in Analyst Recommendations: Alector, Inc.

e0df8c00bf844390e03914.FW4viXP0YssilwVZiKoHdfzsnVxy7_nr-0phmqWS5zc.TVcX3gbBUbtu80dguttJHKaBrmhLvc67rn4W6tfd31pPDV-4NKYSrFrNag~d2de3ce780b853a79942c8788a925a67

Analysts' recommendations: Alector, Inc.

04-15	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
04-15	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
03-10	Alector Shares Rise After BTIG Upgrade	MT
03-10	BTIG Upgrades Alector to Buy From Neutral, Price Target is $6	MT
25-10-22	Top Midday Decliners	MT
25-10-22	William Blair Downgrades Alector to Market Perform From Outperform	MT
25-10-22	TD Cowen Downgrades Alector to Hold From Buy	MT
25-10-22	BTIG Downgrades Alector to Neutral From Buy	MT
25-10-22	Cantor Fitzgerald Downgrades Alector to Neutral From Overweight	MT
25-10-22	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $1.50 From $3.50	MT
25-07-28	Alector Shares Rise After Mizuho Upgrade	MT
25-07-28	Mizuho Upgrades Alector to Outperform From Neutral, Raises Price Target to $3.50 From $2.50	MT
24-12-17	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9	MT
24-12-16	Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15	MT
24-12-04	BofA Securities Downgrades Alector to Underperform	MT
23-12-14	Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	MT
23-12-12	Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	MT
23-11-16	Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating	MT
23-09-22	Cantor Fitzgerald Starts Alector at Overweight With $13 Price Target	MT
23-08-11	Mizuho Cuts Price Target on Alector to $10 From $12, Keeps Buy Rating	MT
23-08-08	Stifel Adjusts Price Target on Alector to $8 From $10, Maintains Hold Rating	MT
23-05-05	Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating	MT
23-03-03	Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating	MT
23-03-02	BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating	MT
23-03-02	Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALECTOR, INC.					+44.86%
	WUXI APPTEC CO., LTD.					+23.69%
	ARGENX SE					+18.14%
	INSMED INCORPORATED					+54.69%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.66%
	BIONTECH SE					+23.2%
	GENMAB A/S					+17.29%
	PHARMAESSENTIA CORPORATION					+9.16%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.94%
	SUMMIT THERAPEUTICS INC.					+66.2%
	Average					+31.38%
	Weighted average by Cap.					+26.95%